Lecap Asset Management Ltd. Takes $2.06 Million Position in Cencora, Inc. (NYSE:COR)

Lecap Asset Management Ltd. acquired a new position in Cencora, Inc. (NYSE:COR - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 9,163 shares of the company's stock, valued at approximately $2,062,000.

Several other institutional investors have also recently made changes to their positions in the business. Stanley Laman Group Ltd. lifted its stake in shares of Cencora by 2.1% in the 3rd quarter. Stanley Laman Group Ltd. now owns 19,754 shares of the company's stock worth $4,446,000 after purchasing an additional 401 shares during the period. Waldron Private Wealth LLC lifted its stake in shares of Cencora by 31.5% in the 3rd quarter. Waldron Private Wealth LLC now owns 1,469 shares of the company's stock worth $331,000 after purchasing an additional 352 shares during the period. Eastern Bank purchased a new stake in Cencora in the 3rd quarter worth approximately $130,000. Sequoia Financial Advisors LLC increased its holdings in Cencora by 23.1% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 6,630 shares of the company's stock worth $1,492,000 after acquiring an additional 1,245 shares in the last quarter. Finally, Foundations Investment Advisors LLC increased its holdings in Cencora by 35.8% in the 3rd quarter. Foundations Investment Advisors LLC now owns 5,287 shares of the company's stock worth $1,190,000 after acquiring an additional 1,395 shares in the last quarter. Institutional investors own 97.52% of the company's stock.

Insiders Place Their Bets

In other Cencora news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of Cencora stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the completion of the transaction, the insider now directly owns 19,980,000 shares of the company's stock, valued at $4,806,388,800. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Chairman Steven H. Collis sold 21,509 shares of the business's stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the sale, the chairman now directly owns 285,088 shares of the company's stock, valued at approximately $67,223,750.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the business's stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the sale, the insider now directly owns 19,980,000 shares of the company's stock, valued at $4,806,388,800. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 4,461,153 shares of company stock valued at $1,073,075,720 over the last three months. 15.80% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on COR. StockNews.com lowered shares of Cencora from a "strong-buy" rating to a "buy" rating in a report on Friday, September 20th. Robert W. Baird reduced their target price on shares of Cencora from $287.00 to $283.00 and set an "outperform" rating for the company in a report on Friday, September 6th. Evercore ISI reduced their target price on shares of Cencora from $270.00 to $250.00 and set an "outperform" rating for the company in a report on Tuesday, October 8th. Wells Fargo & Company increased their target price on shares of Cencora from $236.00 to $249.00 and gave the stock an "equal weight" rating in a report on Thursday, August 1st. Finally, Bank of America reaffirmed a "neutral" rating and set a $245.00 price objective (down from $275.00) on shares of Cencora in a report on Wednesday, September 18th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $259.44.

Cencora Price Performance

COR traded up $0.35 during trading hours on Wednesday, hitting $234.52. The company's stock had a trading volume of 755,044 shares, compared to its average volume of 1,415,713. The business's 50-day moving average price is $232.32 and its 200-day moving average price is $230.85. Cencora, Inc. has a 12 month low of $182.75 and a 12 month high of $247.66. The stock has a market cap of $46.78 billion, a price-to-earnings ratio of 25.62, a P/E/G ratio of 1.40 and a beta of 0.44. The company has a current ratio of 0.89, a quick ratio of 0.55 and a debt-to-equity ratio of 3.93.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, topping the consensus estimate of $3.18 by $0.16. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The company had revenue of $74.20 billion for the quarter, compared to analysts' expectations of $73.32 billion. During the same quarter in the previous year, the business posted $2.92 earnings per share. Cencora's quarterly revenue was up 10.8% on a year-over-year basis. Sell-side analysts expect that Cencora, Inc. will post 13.63 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 9th were paid a dividend of $0.51 per share. This represents a $2.04 annualized dividend and a yield of 0.87%. The ex-dividend date of this dividend was Friday, August 9th. Cencora's payout ratio is 22.32%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.